Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine

NCT: NCT07719608 · RECRUITING

NCT IDNCT07719608
StatusRECRUITING
Start Date2026-12-01
Completion2031-05-01
SponsorSalvia BioElectronics (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this pivotal clinical study is to evaluate the safety and effectiveness of the MySalvia System, a minimally invasive implantable neuromodulation therapy, for the preventive treatment of adults with resistant migraine.

Frequently Asked Questions

What is A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine?

A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine is a clinical trial registered under NCT07719608. Current status: RECRUITING.

What is the status of NCT07719608?

The current status of NCT07719608 (A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine) is: RECRUITING.

When did A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine start?

A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine started on 2026-12-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑